GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Total Inventories

AngioDynamics (AngioDynamics) Total Inventories : $58.1 Mil (As of Feb. 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Total Inventories?

AngioDynamics's total inventories for the quarter that ended in Feb. 2024 was $58.1 Mil. AngioDynamics's average total inventories from the quarter that ended in Nov. 2023 to the quarter that ended in Feb. 2024 was $61.2 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. AngioDynamics's Net-Net Working Capital per share for the quarter that ended in Feb. 2024 was $0.95.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AngioDynamics's Days Inventory for the three months ended in Feb. 2024 was 141.93.

Inventory Turnover measures how fast the company turns over its inventory within a year. AngioDynamics's Inventory Turnover for the quarter that ended in Feb. 2024 was 0.64.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AngioDynamics's Inventory-to-Revenue for the quarter that ended in Feb. 2024 was 0.81.


AngioDynamics Total Inventories Historical Data

The historical data trend for AngioDynamics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Total Inventories Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.07 59.91 48.61 51.39 55.33

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.53 55.33 59.97 64.25 58.07

AngioDynamics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


AngioDynamics  (NAS:ANGO) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

AngioDynamics's Net-Net Working Capital Per Share for the quarter that ended in Feb. 2024 is

Net-Net Working Capital Per Share (Q: Feb. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(78.451+0.75 * 49.475+0.5 * 58.068-106.144
-0-0)/40.4245
=0.95

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AngioDynamics's Days Inventory for the three months ended in Feb. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Feb. 2024 )/Cost of Goods Sold (Q: Feb. 2024 )*Days in Period
=61.161/39.321*365 / 4
=141.93

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

AngioDynamics's Inventory Turnover for the quarter that ended in Feb. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Feb. 2024 ) / Average Total Inventories (Q: Feb. 2024 )
=39.321 / 61.161
=0.64

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AngioDynamics's Inventory to Revenue for the quarter that ended in Feb. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=61.161 / 75.182
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


AngioDynamics Total Inventories Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421